These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 31787605)

  • 41. Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate.
    Kobayakawa T; Kojima T; Takahashi N; Hayashi M; Yabe Y; Kaneko A; Shioura T; Saito K; Hirano Y; Kanayama Y; Miyake H; Asai N; Funahashi K; Hirabara S; Hanabayashi M; Asai S; Ishiguro N
    Mod Rheumatol; 2015 Mar; 25(2):251-6. PubMed ID: 25211402
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H; Frisell T; Askling J;
    JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting.
    Liang H; Danwada R; Guo D; Curtis JR; Kilpatrick RD; Hendrickson B; Islam SS
    RMD Open; 2019; 5(2):e001013. PubMed ID: 31673413
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies.
    Favalli EG; Biggioggero M; Marchesoni A; Meroni PL
    Rheumatology (Oxford); 2014 Sep; 53(9):1664-8. PubMed ID: 24729445
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N; Betts KA; Messali AJ; Skup M; Garg V
    Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study.
    Buchbinder R; Van Doornum S; Staples M; Lassere M; March L
    BMC Musculoskelet Disord; 2015 Oct; 16():309. PubMed ID: 26481039
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
    Frisell T; Baecklund E; Bengtsson K; Di Giuseppe D; Forsblad-d'Elia H; Askling J;
    Ann Rheum Dis; 2018 May; 77(5):650-657. PubMed ID: 29237621
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Persistence to Biologic Therapy Among Patients With Ankylosing Spondylitis: An Observational Study Using the OPAL Dataset.
    Griffiths H; Smith T; Mack C; Leadbetter J; Butcher B; Acar M; Ciciriello S
    J Rheumatol; 2022 Feb; 49(2):150-156. PubMed ID: 34334362
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improvement in clinical disease activity index when treatment selection is informed by the tumor necrosis factor-ɑ inhibitor molecular signature response classifier: analysis from the study to accelerate information of molecular signatures in rheumatoid arthritis.
    Strand V; Zhang L; Arnaud A; Connolly-Strong E; Asgarian S; Withers JB
    Expert Opin Biol Ther; 2022 Jun; 22(6):801-807. PubMed ID: 35442122
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cycling of tumor necrosis factor inhibitors
    Migliore A; Pompilio G; Integlia D; Zhuo J; Alemao E
    Ther Adv Musculoskelet Dis; 2021; 13():1759720X211002682. PubMed ID: 33854570
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Retrospective analysis to describe associations between tumor necrosis factor alpha inhibitors and COPD-related hospitalizations.
    Accortt NA; Chung JB; Bonafede M; Limone BL; Mannino DM
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2085-2094. PubMed ID: 28790811
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative effectiveness of treatments for rheumatoid arthritis in clinical practice: A systematic review.
    Sparks JA; Harrold LR; Simon TA; Wittstock K; Kelly S; Lozenski K; Khaychuk V; Michaud K
    Semin Arthritis Rheum; 2023 Oct; 62():152249. PubMed ID: 37573754
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis.
    Chastek B; Becker LK; Chen CI; Mahajan P; Curtis JR
    J Med Econ; 2017 May; 20(5):464-473. PubMed ID: 28010149
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns for Rheumatoid Arthritis Among United States Physicians.
    Sullivan E; Kershaw J; Blackburn S; Choi J; Curtis JR; Boklage S
    Rheumatol Ther; 2020 Jun; 7(2):383-400. PubMed ID: 32318979
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry.
    Monti S; Klersy C; Gorla R; Sarzi-Puttini P; Atzeni F; Pellerito R; Fusaro E; Paolazzi G; Rocchetta PA; Favalli EG; Marchesoni A; Caporali R
    Clin Rheumatol; 2017 Apr; 36(4):753-761. PubMed ID: 28058538
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-world evaluation of effectiveness, persistence, and usage patterns of tofacitinib in treatment of rheumatoid arthritis in Australia.
    Bird P; Littlejohn G; Butcher B; Smith T; da Fonseca Pereira C; Witcombe D; Griffiths H
    Clin Rheumatol; 2020 Sep; 39(9):2545-2551. PubMed ID: 32157469
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biologic prescribing decisions following serious infection: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis.
    Subesinghe S; Rutherford AI; Byng-Maddick R; Hyrich KL; Galloway JB
    Rheumatology (Oxford); 2018 Dec; 57(12):2096-2100. PubMed ID: 29986108
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register.
    Chatzidionysiou K; Askling J; Eriksson J; Kristensen LE; van Vollenhoven R;
    Ann Rheum Dis; 2015 May; 74(5):890-6. PubMed ID: 24431398
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Guided therapy selection in rheumatoid arthritis using a molecular signature response classifier: an assessment of budget impact and clinical utility.
    Arnell C; Bergman M; Basu D; Kenney JT; Withers JB; Logan J; Harashima JL; Connolly-Strong E
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1734-1742. PubMed ID: 34669487
    [No Abstract]   [Full Text] [Related]  

  • 60. Most Appropriate Conventional Disease-Modifying Antirheumatic Drug to Combine With Different Advanced Therapies in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis.
    Decarriere G; Barnetche T; Combe B; Gaujoux-Viala C; Lukas C; Morel J; Daien C
    Arthritis Care Res (Hoboken); 2021 Jun; 73(6):873-884. PubMed ID: 32216091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.